Free shipping on all orders over $ 500

Peficitinib

Cat. No. M9147

All AbMole products are for research use only, cannot be used for human consumption.

Peficitinib Structure
Synonym:

ASP015K; JNJ-54781532

Size Price Availability Quantity
1mg USD 40  USD40 In stock
5mg USD 80  USD80 In stock
10mg USD 135  USD135 In stock
25mg USD 240  USD240 In stock
50mg USD 380  USD380 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Peficitinib (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively. Peficitinib suppresses the IL-2-induced proliferation of human T cells with greater potency than EPO-induced proliferation of human erythroleukemia cells. In human whole blood, ASP015K inhibits STAT5 phosphorylation (pSTAT5).

In vivo, Peficitinib (20 mg/kg, p.o.) suppresses IL-2-induced STAT5 phosphorylation by 78% in the rat model of adjuvant-induced arthritis (AIA). Peficitinib potently inhibits the increase in paw volume (≥1 mg/kg) with an ED50 of 2.7 mg/kg, significantly reduces the bone destruction score (≥10 mg/kg) and almost fully ameliorates both paw swelling and bone destruction scores (30 mg/kg).

Chemical Information
Molecular Weight 326.39
Formula C18H22N4O2
CAS Number 944118-01-8
Solubility (25°C) DMSO: ≥ 55 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Yoshiya Tanaka, et al. Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis

[2] Yuko Kaneko. Efficacy and safety of peficitinib in rheumatoid arthritis

[3] Young Ho Lee, et al. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis

[4] Tsutomu Takeuchi, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan

[5] Anthony Markham, et al. Peficitinib: First Global Approval

Related JAK Products
iJak-381 

iJak-381 is a JAK1/2 inhibitor with anti-inflammatory activity.

Ritlecitinib (malonate)

Ritlecitinib (PF-06651600) malonate is an orally active and selective JAK3 inhibitor with an IC50 of 33.1 nM.

Deuruxolitinib

Deuruxolitinib is a deuterated Ruxolitinib (INCB18424), which modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research of hair loss disorders.

A-005

A-005 is a potentially first-in-class, brain-penetrating TYK2 allosteric inhibitor for studies related to neuroinflammatory and neurodegenerative diseases.

Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)

Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

  Catalog
Abmole Inhibitor Catalog




Keywords: Peficitinib, ASP015K; JNJ-54781532 supplier, JAK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.